Overview

Immunotherapy Before and After Surgery

Status:
NOT_YET_RECRUITING

Trial end date:
2031-06-30

Target enrollment:

Participant gender:

Summary

This Phase 2 clinical trial is testing a new immunotherapy combination (N-803, ETBX-071, M-CENK) for men with high-risk prostate cancer before and after prostate surgery. The goal is to see if this treatment improves cancer outcomes and is safe.

Phase:

PHASE2

Details

Lead Sponsor:

ImmunityBio, Inc.

Treatments:

ALT-803